Perpetuals.com (NASDAQ: PDC) announced the expansion of its BayesShield AI technology into healthcare with the launch of BayesShield Clinical, designed to identify physicians with the strongest diagnostic accuracy across specific case types. The platform applies the company’s statistical methodology, originally developed for financial markets, to reduce bias and improve clinical decision-making, with initial deployment supported through a partnership with the European Institute of Management to oversee pilot programs and academic validation.
This move marks a significant step for the fintech company as it extends its AI methodology to healthcare and other decision-intensive domains through BayesShield. Perpetuals’s proprietary trading platform, Kronos X, combines advanced AI and data analysis, trained on billions of trades, monitors market activity in real time, identifies patterns for trading and risk decisions, and provides multi-asset coverage with self‑clearing blockchain-based settlement. The company’s licensed European Multilateral Trading Facility (MTF) infrastructure and Kronos X multi‑asset exchange platform operate with full MiFID II, MiCA, DORA, and EMIR compliance.
Perpetuals CEO Patrick Gruhn is a Professor and PhD candidate for computer science and engineering, and founder of the Patrick Gruhn Institute at the EIM. The latest news and updates relating to PDC are available in the company’s newsroom at https://ibn.fm/PDC.
The implications of this announcement are far-reaching. By adapting its statistical methodology from financial markets to healthcare, Perpetuals aims to reduce diagnostic bias and improve clinical decision-making. This could lead to more accurate diagnoses, better patient outcomes, and potentially lower healthcare costs. The partnership with the European Institute of Management provides academic validation and structured pilot programs, ensuring the technology is rigorously tested before widespread adoption. The BayesShield Clinical platform represents a convergence of fintech and healthtech, highlighting the versatility of AI-driven statistical models across different sectors.
For investors, this expansion signals Perpetuals’ commitment to diversifying its AI applications beyond trading, potentially opening new revenue streams and market opportunities. The company’s existing regulatory compliance (MiFID II, MiCA, DORA, EMIR) and established infrastructure provide a solid foundation for this healthcare venture. The news also underscores the growing trend of cross-industry AI applications, where technologies developed for one domain are adapted to solve challenges in another. For the full press release, visit https://ibn.fm/wdRRE.
